WIM
SEEL

WealthPlan Investment Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

WealthPlan Investment Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20
Closed -$55.9K – 590
2022
Q4 		$55.9K Sell
20
-1
-5% -$3.49K ﹤0.01% 386
2022
Q3 		$86K Buy
+21
New +$82.6K 0.01% 363
2022
Q1 		$33K Buy
+14
New +$60.2K ﹤0.01% 379

Other funds holding SEEL

GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WealthPlan Investment Management's SEEL Position: Q1 2023 in Review

WealthPlan Investment Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2023, closing a stake of 20 shares — an estimated $55.9K sold.

WealthPlan Investment Management first reported a position in SEEL in Q1 2022 and held it in 3 quarters. The position peaked at $86K in Q3 2022. 60 funds tracked by Wall St. Rank hold SEEL as of Q1 2023.

  • WealthPlan Investment Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • WealthPlan Investment Management sold 20 Seelos Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $55.9K.
  • WealthPlan Investment Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • WealthPlan Investment Management's Seelos Therapeutics, Inc. Common Stock position peaked at $86K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2023.

Based on WealthPlan Investment Management's 13F filing for Q1 2023, filed 8 May 2023.